Novartis Just Paid $1.4 Billion to Fight Heart Attacks With Inflammation
Novartis is paying $1.4 billion for Tourmaline Bio and its anti-IL-6 antibody, betting that inflammation (not just cholesterol) is the key to preventing heart attacks. The science is compelling, but the real test is still ahead.
Imagine you've been treating heart disease for decades with the same basic toolkit: lower cholesterol, thin the blood, manage blood pressure. Then someone walks in and says, "What if we've been ignoring a whole other cause of heart attacks this entire time?"
That's the bet Novartis just made. The Swiss pharma giant is acquiring Tourmaline Bio for approximately $1.4 billion, paying $48 per share in cash to get its hands on a single experimental drug called pacibekitug. It's a monoclonal antibody (a lab-made protein designed to block a specific target in the body) that goes after IL-6, an inflammatory molecule that scientists increasingly believe is a hidden driver of heart disease.
The deal carries a 59% premium to Tourmaline's last closing price and a staggering 127% premium to its 60-day average trading price. That's not a casual handshake. That's Novartis walking into the room, slamming its credit card on the table, and saying, "We believe in this."
The Inflammation Theory of Heart Attacks
For most of modern medicine, the story of heart disease has been about plaque buildup in arteries. Cholesterol gets too high, fatty deposits accumulate, arteries narrow, bad things happen. Statins revolutionized treatment by attacking that cholesterol problem head-on.
But there's a frustrating reality cardiologists know well: some patients do everything right. Their LDL cholesterol is low. They take their medications. And they still have heart attacks. Something else is going on, and over the past decade, the finger has increasingly pointed at chronic inflammation.
IL-6 (interleukin-6) is one of the body's key inflammatory signals. Think of it like a fire alarm that won't stop ringing. In healthy people, IL-6 helps coordinate immune responses. But when it's chronically elevated, it appears to accelerate the process that makes arterial plaques unstable and prone to rupture. Genetic studies have even shown that people born with naturally higher IL-6 signaling face greater risk of coronary disease and stroke.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The proof of concept came from a landmark trial called CANTOS, which tested a drug called canakinumab. That drug didn't target IL-6 directly; it blocked IL-1β, a molecule upstream of IL-6 in the inflammatory cascade. The results were striking: fewer heart attacks and strokes, without any changes to patients' cholesterol levels. It was like discovering that you could prevent car crashes not just by fixing the brakes, but by smoothing out the road.
The catch? Canakinumab never became a blockbuster heart drug. It was expensive, carried infection risks, and never gained broad adoption for cardiovascular use. Colchicine, a cheap, old anti-inflammatory, has shown some benefit in secondary prevention trials, but it's a blunt instrument.
What nobody has done yet is go directly after IL-6 itself in a large cardiovascular outcomes trial. That's exactly what pacibekitug is designed to do.
What Tourmaline Actually Built
Tourmaline Bio was founded in September 2021 by Sandeep Kulkarni and Caley Castelein with a focused mission: develop treatments for inflammatory diseases. The company licensed pacibekitug from Pfizer in 2022 (Pfizer had shelved the drug, which is a bit like finding a vintage guitar in someone's attic). Tourmaline went public through a reverse merger with Talaris Therapeutics in October 2023, then raised $150 million in a January 2024 underwritten public offering at $32.50 per share.
Early backers included Deep Track Capital, Cowen Healthcare Investments, TCGX, Great Point Partners, and several others. This wasn't a company that struggled to find believers.
The key data come from the Phase 2 TRANQUILITY trial, which tested pacibekitug in patients with elevated hs-CRP (a blood marker of inflammation) and chronic kidney disease. The results were genuinely impressive.
Patients on the drug saw their hs-CRP levels plummet. The median reduction through Day 90 ranged from 75% to 86% depending on the dose, compared with a 15% increase for placebo. All dosing arms hit statistical significance with a p-value below 0.0001.
Perhaps more importantly, at Day 90 between 77% and 88% of treated patients got their hs-CRP below 2 mg/L (a clinically meaningful threshold), versus only 13% on placebo. If hs-CRP is the fire alarm, pacibekitug essentially turned the volume from a blaring siren to a whisper.
The safety profile looked clean, too. Adverse events were comparable to placebo. No serious injection-site reactions. No significant drops in blood cell counts. No worrisome changes in cholesterol or triglycerides. One death occurred in the trial: a fatal COVID-19 case, which wasn't attributed to the drug.
The Billion-Dollar Caveat
All of this sounds great, but there's a crucial asterisk: reducing an inflammatory biomarker is not the same as preventing heart attacks. We've seen this movie before in biotech. Drugs that move lab numbers beautifully sometimes fail to improve actual patient outcomes.
Pacibekitug hasn't been tested in a Phase 3 cardiovascular outcomes trial yet. That means we don't have evidence showing it reduces heart attacks, strokes, or cardiovascular deaths. The Phase 2 data support starting that trial, but starting a race and winning it are very different things.
Novartis is essentially paying $1.4 billion for a very compelling hypothesis backed by strong biomarker data, solid genetics, and the CANTOS precedent. It's like buying a house based on a phenomenal inspection report before you've actually lived through a winter. Probably fine. But not guaranteed.
Why Novartis, and Why Now
This deal makes a lot more sense when you zoom out and look at what Novartis is building. The company is constructing an entire post-Entresto cardiovascular franchise. Entresto (their blockbuster heart failure drug) won't be on patent forever, and Novartis has been stacking the deck:
Pelacarsen targets Lp(a), a genetically driven cardiovascular risk factor, with outcomes data expected from a major trial.
Abelacimab (acquired via Anthos Therapeutics) is a Factor XI inhibitor aimed at stroke prevention in atrial fibrillation.
RNA-based programs through a multi-year collaboration with Argo Biopharmaceutical are exploring next-generation lipid-lowering approaches.
A $100 million collaboration with Unnatural Products is developing peptide drugs for hard-to-reach cardiovascular targets.
Pacibekitug fills the inflammation slot in this portfolio. Novartis isn't placing one big bet on the future of cardiology; it's placing five or six medium-sized bets across different biological mechanisms. If even two or three pay off, the franchise is built.
The company also brings something Tourmaline couldn't easily replicate on its own: the infrastructure and expertise to run a massive cardiovascular outcomes trial. These trials are expensive, logistically brutal, and can take years to read out. For a small biotech trading in the $20s before the deal, that's a tall order. For Novartis, it's Tuesday.
What Wall Street Thinks
Analysts were broadly positive on the strategic logic. Truist called it "a good deal." Several firms effectively endorsed the offer price by adjusting their ratings to reflect the $48 buyout.
The cautionary notes were subtle but real. Novartis shares dipped on the announcement, which sometimes happens when a big pharma company writes a large check for an asset that won't generate revenue for years. Some commentary framed the deal as part of a more careful M&A environment where pharma companies are favoring focused, digestible acquisitions over mega-mergers.
At $1.4 billion, this is meaningful but manageable for Novartis. It's not betting the farm. It's planting a new field.
The Bigger Picture
The Tourmaline deal is really a referendum on one of the most important questions in modern cardiology: can we prevent heart attacks by putting out the fire of inflammation?
CANTOS proved the concept works in principle. Colchicine nudged the door open a little wider. But nobody has walked through with a purpose-built IL-6 inhibitor and a clean Phase 3 outcomes trial. If pacibekitug pulls that off, it could open up a treatment paradigm for millions of patients who remain at risk despite taking statins and controlling their traditional risk factors.
The estimated market opportunity? Analysts have described it as potentially multi-billion dollars if the outcomes data deliver. Residual inflammatory risk (the leftover danger even after cholesterol is managed) affects a huge population, and there's no approved IL-6 inhibitor targeting it.
Of course, "if" is doing a lot of heavy lifting in that sentence. Phase 3 outcomes trials in cardiovascular disease are notoriously difficult. Patient populations are large. Timelines are long. And the bar for proving that a new drug actually saves lives is, rightly, very high.
But Novartis clearly thinks the science is ready. They paid a 127% premium over the 60-day average for that conviction. In a pharma landscape where everyone is hunting for the next growth engine, Novartis has decided that the future of heart disease might not be about cholesterol at all. It might be about cooling the flames.
Clinical & Regulatory
4 min read
The Government Wants an AI Doctor for Your Heart
ARPA-H just bet $62.7 million that an AI can manage heart failure patients around the clock, prescribing drugs and ordering tests without waiting for a doctor. If it works, it could reshape how we treat the fastest-growing heart condition in America.
